IMO ... and it is just that ..... CLBP relief for even 6 months after a stem cell treatment would still negate the need for these patients to use opioids during this period and subsequently contribute to the decline in opioid dependence / abuse ... our previous trials had exceptional results beyond this time frame !!
A reduction in overall opioid use / abuse is a not only a key focus of the FDA right now, but also for other countries as well (e.g. Australia) .... I wouldn’t be at all surprised if the FDA is communicating a willingness to assist MSB where it can with MPC -06 ID ..... e.g Fast Tracking or RMAT designation ?
GLTAH
Disc Repair (Back Pain Trial), page-17
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |